Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

BACKGROUND: Interleukin (IL) inhibitors achieve greater levels of efficacy than older systemic therapies. We calculated the number needed to treat (NNT) of ixekizumab compared with other IL inhibitors approved in Italy for the treatment of moderate-to-severe plaque psoriasis. METHODS: The clinical e...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravasio, Roberto, Costanzo, Antonio, Antonelli, Silvia, Maiorino, Alessia, Losi, Serena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616200/
https://www.ncbi.nlm.nih.gov/pubmed/36627878
http://dx.doi.org/10.33393/grhta.2021.2222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616200/
https://www.ncbi.nlm.nih.gov/pubmed/36627878
http://dx.doi.org/10.33393/grhta.2021.2222

Ejemplares similares